ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2040

Distinguishing Multisystem Inflammatory Syndrome in Children from Typhus Using Artificial Intelligence: MISC vs. Endemic Typhus (AI-MET)

Angela Chun1, Abraham Bautista-Castillo2, Isabella Osuna1, Kristiana Nasto1, Flor Munoz3, Gordon Schutze1, Sridevi Devaraj1, Eyal Muscal4, Marietta De Guzman5, Kristen Sexson Tejtel1, Ioannis Kakadiaris2 and Tiphanie Vogel1, 1Baylor College of Medicine / Texas Children's Hospital, Houston, TX, 2Computational Biomedicine Lab University of Houston, Houston, TX, 3Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 4Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, 5Baylor College of Medicine, Houston, TX

Meeting: ACR Convergence 2023

Keywords: Bioinformatics, COVID-19, Decision analysis, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) following SARS-CoV2infection is a recognized mimic of other inflammatory disorders, including Kawasaki Disease and macrophage activation syndrome. However, MIS-C can also mimic acute infections, such as endemic typhus, presenting a diagnostic challenge with discordant treatments. We aimed to use artificial intelligence (AI) to develop a clinical decision support system that rapidly and accurately distinguishes MIS-C versus Endemic Typhus (MET).

Methods: With local IRB approval, 49 demographic, clinical, and laboratory features (21 categorical and 28 continuous) available within 6 hours of presentation were retrospectively extracted from the electronic medical records of 133 MIS-C and 87 typhus patients admitted to a single quaternary pediatric system between January 1, 2020 and December 31, 2021. Laboratory values were considered high, low or normal based on institutional norms. Using the attention module of a deep learning model and prioritizing accuracy, during training and testing we iteratively narrowed down to the 30 features necessary to maintain complete accuracy in classification. The AI-MET clinical decision support system was built to use these 30 clinical features, combined with the importance assigned to them by the attention module, to assist providers in distinguishing between MIS-C and typhus manually (i.e., without software) as often as possible.

Results: AI-MET is a two-phase clinical decision support system. In phase 1 of AI-MET, a provider uses 17 features to manually calculate a score (MET-17) to arrive at a diagnostic classification (Table I). If the MET-17 score does not surpass a pre-determined confidence level, 13 additional features are added and the MET-30 score is calculated using a recurrent neural network. While 24 of the 30 features (80%) were statistically different between patients with MIS-C and typhus, values for each feature alone were so overlapping between the two patient groups that the features were irrelevant distinguishers as individual parameters. However, AI-MET successfully classified all 220 typhus and MIS-C patients with 100% accuracy. Approximately half of the patients were classified manually with sufficient confidence during phase I using MET-17 that MET-30 (i.e., software) was not needed. A validation cohort of 111 additional MIS-C patients with all 30 AI-MET features available was also classified as MIS-C with 99% accuracy (110/111).

Conclusion: There is significant diagnostic overlap between MIS-C and endemic typhus. Artificial intelligence can successfully distinguish these diagnoses using features typically available within the first 6 hours of patient presentation. As a clinical decision support system, AI-MET will be a valuable tool for front-line providers facing the difficulty of timely diagnosis of a febrile child in endemic areas.

Supporting image 1


Disclosures: A. Chun: None; A. Bautista-Castillo: None; I. Osuna: None; K. Nasto: None; F. Munoz: Gilead, 5, Pfizer, 5, 12, DSMB; G. Schutze: None; S. Devaraj: None; E. Muscal: Sobi, 1, 11; M. De Guzman: None; K. Sexson Tejtel: None; I. Kakadiaris: None; T. Vogel: Moderna, 2, Novartis, 2, Pfizer, 2, SOBI, 2.

To cite this abstract in AMA style:

Chun A, Bautista-Castillo A, Osuna I, Nasto K, Munoz F, Schutze G, Devaraj S, Muscal E, De Guzman M, Sexson Tejtel K, Kakadiaris I, Vogel T. Distinguishing Multisystem Inflammatory Syndrome in Children from Typhus Using Artificial Intelligence: MISC vs. Endemic Typhus (AI-MET) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/distinguishing-multisystem-inflammatory-syndrome-in-children-from-typhus-using-artificial-intelligence-misc-vs-endemic-typhus-ai-met/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinguishing-multisystem-inflammatory-syndrome-in-children-from-typhus-using-artificial-intelligence-misc-vs-endemic-typhus-ai-met/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology